Teenaged, depressed, and treatment resistant: What predicts self-harm?

American Journal of Psychiatry

Volumn 166, Issue 4, 2009, Pages 385-387

  Weissman, Myrna M ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; CYCLOHEXANOL DERIVATIVE;

ADJUVANT THERAPY; ADOLESCENT; ADOLESCENT DISEASE; AUTOMUTILATION; DEPRESSION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SUICIDAL BEHAVIOR; SUICIDE; CHEMICALLY INDUCED DISORDER; COGNITIVE THERAPY; DRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; NOTE; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; RISK FACTOR; SUICIDE ATTEMPT;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG RESISTANCE; HUMANS; RISK ASSESSMENT; RISK FACTORS; SELF-INJURIOUS BEHAVIOR; SEROTONIN UPTAKE INHIBITORS; SUICIDE, ATTEMPTED;

EID: 64949179171     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.09020265     Document Type: Editorial

References (11)

1. Olfson M, Marcus SC, Druss BG: Effects of Food and Drug Administration warnings on antidepressant use in the national sample. Arch Gen Psychiatry 2008; 65:94-101
2. Jureidini J: The black box warning: decreased prescriptions and increased youth suicide? Am J Psychiatry 2007; 164:1907-1908
3. Olfson M, Shaffer D: Withdrawal of attention rather than pharmacological treatment affects suicide rates in depressed children and adolescents. Am J Psychiatry 2007; 164:1908
4. Brent D: Antidepressants and suicidal behavior: cause or cure? Am J Psychiatry 2007; 164:989-991
5. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164:1035-1043 (Pubitemid 47121392)
6. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J: Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299:901-913
7. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, DeBar LL, McCracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB: Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009; 166:418-426
8. Hammad TA: Relational between psychotropic drugs and pediatric suicidality. Food and Drug Administration. Aug 16, 2004; p 19
9. Jacobson CM, Gould M: The epidemiology and phenomenology of non-suicidal self-injurious behavior among adolescents: a critical review of the literature. Arch Suicide Res 2007; 11:129-147
10. Hilt LM, Cha CB, Nolen-Hoeksema S: Nonsuicidal self-injury in young adolescent girls: moderators of the distress-function relationship. J Consult Clin Psychol 2008; 76:63-71
11. Laughren TP: Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee (PDAC) [memorandum]. Available at http://www.fda.gov/ ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf